Case 1

Albain K et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). SABCS 2007;Abstract 10.

Dowsett M et al. Risk of distant recurrence using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: A TransATAC study. SABCS 2008;Abstract 53.

Forbes JF et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9(1):45-53. Abstract

Goldstein LJ et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008;26(25):4063-71. Abstract

Goldstein LJ et al. Prognostic utility of 21- gene assay in hormone receptor (HR) positive operable breast cancer and 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): An analysis of Intergroup trial E2197. Proc ASCO 2007;Abstract 526.

Ingle JN et al. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: Meta-analyses of randomized trials of monotherapy and switching strategies. SABCS 2008;Abstract 12.

Jones SE et al. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: Docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. SABCS 2007;Abstract 12.

Mouridsen HT et al. BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. SABCS 2008;Abstract 13.

Case 2

Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: A new frontier in symptom management for breast cancer survivors. J Clin Oncol 2007;25(25):3797-9. Abstract

Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007;16(3):223-34. Abstract

Coleman RE et al. Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. Cancer Treat Rev 2008;34(3):275-82. Abstract

Crew KD et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitorsor early-stage breast cancer. J Clin Oncol 2007;25(25):3877-83. Abstract

Cuzick J et al. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial. Lancet Oncol 2008;9(12):1143-8. Abstract

Goss PE et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26(12):1948-55. Abstract

Ingle JN et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008;19(5):877-82. Abstract

Morales L et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008;26(19):3147-52. Abstract

Muss HB et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 2008;26(12):1956-64. Abstract

Sestak I et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: A retrospective, exploratory analysis. Lancet Oncol 2008;9(9):866-72. Abstract

Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol 2007;14(Suppl 1):11-9. Abstract

Case 3

Buzdar AU et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13(1):228-33. Abstract

Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008;31(6):459-67. Abstract

Gianni L et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: Primary efficacy analysis of the NOAH trial. San Antonio Breast Cancer Symposium 2008;Abstract 31.

Jones SE et al. Preliminary toxicity results of a phase II trial of adjuvant docetaxel/ cyclophosphamide plus trastuzumab in HER2+ early stage breast cancer patients. SABCS 2008;Abstract 2111.

Perez EA et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26(8):1231-8. Abstract

Pinder MC et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007;25(25):3808-15. Abstract

Popat S, Smith IE. Therapy insight: Anthracyclines and trastuzumab — The optimal management of cardiotoxic side effects. Nat Clin Pract Oncol 2008;5(6):324-35. Abstract

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Sengupta PP et al. Trastuzumab-induced cardiotoxicity: Heart failure at the crossroads. Mayo Clin Proc 2008;83(2):197-203. Abstract

Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. SABCS 2006;Abstract 52.

Smith I et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369(9555):29-36. Abstract

Suter TM et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol 2007;25(25):3859-65. Abstract

Telli ML et al. Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 2007;25(23):3525-33. Abstract

Untch M et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19(6):1090-6. Abstract

Viani GA et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer 2007;7:153. Abstract

Case 4

Amar S et al. Prognosis and clinical outcome of patients with node negative < 1 cm breast cancer. SABCS 2007;Abstract 6024.

Ananthakrishnan P et al. HER2 amplification does not alter outcome in small (<1 cm) tumors. SABCS 2008;Abstract 6058.

Black D et al. Recurrence risk in T1a-b, node negative, HER2 positive breast cancer. SABCS 2006;Abstract 2037.

Chia S et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008;26(35):5697-704. Abstract

Norris B et al. Poor 10 yr breast cancer specific survival (BCSS) and relapse free survival (RFS) for HER-2 positive T1pN0 tumors. SABCS 2006;Abstract 2031.

Rakkhit R et al. Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. SABCS 2008;Abstract 701.

Schmidt M et al. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res 2005;7:R256-66. Abstract

Tovey SM et al. Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours. Implications for trastuzumab therapy? SABCS 2008;Abstract 702.

Untch M et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19(6):1090-6. Abstract

Bartlett JMS et al. Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: Emerging evidence from the UK NEAT adjuvant breast cancer trial. SABCS 2008;Abstract 45.

Carey LA et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13(8):2329-34. Abstract

Cleator S et al. Triple-negative breast cancer: Therapeutic options. Lancet Oncol 2007;8(3):235-44. Abstract

Finn RS et al. Phase II trial of dasatinib in triple-negative breast cancer: Results of study CA180059. SABCS 2008;Abstract 3118.

Gluz O et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: Results of WSG AM-01 trial. Ann Oncol 2008;19(5):861-70. Abstract

Haffty BG et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24(36):5652-7. Abstract

Kang SP et al. Triple negative breast cancer: Current understanding of biology and treatment options. Curr Opin Obstet Gynecol 2008;20(1):40-6. Abstract

Koster F et al. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. Breast Cancer Res Treat 2008;[Epub ahead of print]. Abstract

Liedtke C et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26(8):1275-81. Abstract

Poole CJ et al; NEAT Investigators and the SCTBG. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006;355(18):1851-62. Abstract

Schneider BP et al. Triple-negative breast cancer: Risk factors to potential targets. Clin Cancer Res 2008;14(24):8010-8. Abstract

Sirohi B et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008;19(11):1847-52. Abstract

Tan AR, Swain SM. Therapeutic strategies for triple-negative breast cancer. Cancer J 2008;14(6):343-51. Abstract

Tan DS et al. Triple negative breast cancer: Molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008;111(1):27-44. Abstract